Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.47 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | SELE | P16581 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | FGF1 | P05230 | 2/20 | 0.39 |
| ▸ | FGF2 | P09038 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476174 | 0.90 | LGALS8 (0.50) | LGALS8F10FGF1FGF2VEGFA | |
| SCHEMBL18122122 | 0.90 | LGALS8 (0.49) | LGALS8STAT3FGF1FGF2VEGFA | |
| SCHEMBL18412621 | 0.88 | SELE (0.43) | LGALS8STAT3SELEFGF1FGF2 | |
| SCHEMBL25455773 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL22097404 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL19153198 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL15851469 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL15625001 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL16382328 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A | |
| SCHEMBL19382503 | 0.88 | LGALS8 (0.48) | LGALS8STAT3SELEFGF1AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MIDCAP FINANCIAL TRUST, AS AGENT | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MANBA, ALG1, MAN2A1 | LGALS8 52/4885STAT3 3918/4885SELE 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.